To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Feb 16, 2022
  • participants needed
    35
  • sponsor
    Veru Inc.
Updated on 7 September 2021

Summary

To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.

Description

This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain and maintain serum total testosterone levels within castrate range (<50ng/dL) in men with advanced prostate cancer. Stage 1 of the study will assess the effect of 150 mg of VERU-100. Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an expanded patient population.

Details
Condition Advanced Prostate Adenocarcinoma
Treatment VERU-100
Clinical Study IdentifierNCT04843319
SponsorVeru Inc.
Last Modified on7 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Be over 18 years of age
Be able to communicate effectively with the study personnel
Have histologically confirmed prostate cancer
Have prostate cancer staged T3-4NxMx or TxN1Mx or TxNxM1 according to the TNM classification or the patient should have rising PSA after failed local therapy and be candidate for androgen deprivation therapy
Subjects are judged by the attending physician and/or Principal Investigator to be a candidate for androgen deprivation therapy (continuous therapy)
Have a QT interval <400 ms
Have a life expectancy of 18 months
ECOG performance status of 0 to 2
Subjects must agree to use acceptable methods of contraception
Baseline morning serum testosterone levels >150 ng/dL at Screening Visit
If their female partners are pregnant or lactating, acceptable methods of contraception from the time of the first administration of study medication until 6months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azoospermia),a condom with spermicidal foam/gel/film/cream/suppository should be used
If the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/cream/suppository [i.e.,barrier method of contraception], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
If the female partner has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
If the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS),a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
Laboratory values within the following ranges: hemoglobin 10 gm/dL, total bilirubin
5 mg/dL, absolute neutrophil count 1500 cell/uL and platelets 100,000 cells/uL
Subject is willing to comply with the requirements of the protocol through the end of the study
5x upper limit of normal (ULN), AST 2.5x ULN, ALT 2.5x ULN
Creatinine clearance 60 mL/min based on Cockcroft-Gault equation

Exclusion Criteria

Prior androgen deprivation therapy within 6 months prior to Screening Visit
History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Received chemotherapy, cryotherapy, or antiandrogen therapy within 8 weeks prior to the Screening visit for the treatment of prostate cancer
Known hypersensitivity to cetrorelix or other LHRH antagonists
Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk
Potentially curable disease receiving ADT for localized disease
Use of exogenous testosterone within 6 months of Screening Visit
Use of 5-reductase inhibitor within 3 months of Screening Visit
Use of systemic corticosteroids at a dose >10 mg/day at Screening
Major surgery within 4 weeks of Screening Visit (including surgery for prostate cancer)
History of Torsade de Pointes
Uncontrolled symptomatic congestive heart failure (NYHA Class III -IV), unstable angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation
Currently taking QT-prolonging drugs
History of diabetes mellitus Type 1. Uncontrolled diabetes mellitus Type 2 (control with oral hypoglycemic agents are allowed)
Received an investigational drug within a period of 90days prior to enrollment in the study
Received the study medication (VERU-100) previously
Have been previously diagnosed or treated for active cancer(other than prostate cancer or non-melanoma skin cancer) within the previous five years
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note